​
​

Cyteir Therapeutics (CYT) Stock Forecast, Price Target & Predictions

OverviewChart

CYT Stock Forecast

Cyteir Therapeutics stock forecast is as follows: an average price target of $2.00 (represents a -33.55% downside from CYT’s last price of $3.01) and a rating consensus of 'Sell', based on 1 wall street analysts offering a 1-year stock forecast.

CYT Price Target

The average price target for Cyteir Therapeutics (CYT) is $2.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential -33.55% downside from CYT's last price of $3.01.

CYT Analyst Ratings

Sell

According to 1 Wall Street analysts, Cyteir Therapeutics's rating consensus is 'Sell'. The analyst rating breakdown for CYT stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 0 'Hold' (0.00%), 1 'Sell' (100.00%), and 0 'Strong Sell' (0.00%).

Cyteir Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 03, 2023-Morgan Stanley$2.00$1.6223.46%-33.55%
Row per page
Go to

The latest Cyteir Therapeutics stock forecast, released on Feb 03, 2023 by Morgan Stanley company, set a price target of $2.00, which represents a 23.46% increase from the stock price at the time of the forecast ($1.62), and a -33.55% decrease from CYT last price ($3.01).

Cyteir Therapeutics Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$3.01$3.01$3.01
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Cyteir Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cyteir Therapeutics's last price of $3.01. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Feb 03, 2023Morgan Stanley-UnderweightDowngrade
Row per page
Go to

Cyteir Therapeutics's last stock rating was published by Morgan Stanley on Feb 03, 2023. The company Downgrade its CYT rating from "null" to "Underweight".

Cyteir Therapeutics Financial Forecast

Cyteir Therapeutics Revenue Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23
Revenue-----
Avg Forecast-----
High Forecast-----
Low Forecast-----
# Analysts-----
Surprise %-----

Cyteir Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CYT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Cyteir Therapeutics EBITDA Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts-----
EBITDA----$-5.17M
Avg Forecast-----
High Forecast-----
Low Forecast-----
Surprise %-----

undefined analysts predict CYT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cyteir Therapeutics's previous annual EBITDA (undefined) of $NaN.

Cyteir Therapeutics Net Income Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts-----
Net Income----$-3.53M
Avg Forecast$55.54M$48.37M$56.80M$-7.21M$-9.01M
High Forecast$55.54M$48.37M$56.80M$-7.21M$-9.01M
Low Forecast$55.54M$48.37M$56.80M$-7.21M$-9.01M
Surprise %----0.39%

Cyteir Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CYT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Cyteir Therapeutics SG&A Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts-----
SG&A----$2.50M
Avg Forecast-----
High Forecast-----
Low Forecast-----
Surprise %-----

Cyteir Therapeutics's average Quarter SG&A projection for Dec 23 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to CYT last annual SG&A of $2.50M (Sep 23).

Cyteir Therapeutics EPS Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts-----
EPS----$-0.10
Avg Forecast$1.54$1.34$1.58$-0.20$-0.25
High Forecast$1.54$1.34$1.58$-0.20$-0.25
Low Forecast$1.54$1.34$1.58$-0.20$-0.25
Surprise %----0.39%

According to undefined Wall Street analysts, Cyteir Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CYT previous annual EPS of $NaN (undefined).

Cyteir Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
NKTXNkarta$2.50$21.60764.00%Buy
PRLDPrelude Therapeutics$0.96$6.25551.04%Sell
LYELLyell Immunopharma$1.03$6.67547.57%Hold
MOLNMolecular Partners$5.20$29.00457.69%Buy
ANEBAnebulo Pharmaceuticals$1.52$6.00294.74%Buy
CCCCC4 Therapeutics$4.05$13.50233.33%Buy
SANASana Bio$2.53$8.00216.21%Buy
RZLTRezolute$5.01$13.50169.46%Buy
NUVBNuvation Bio$2.58$6.75161.63%Buy
ELYMEliem Therapeutics$5.11$13.00154.40%Buy
FHTXFoghorn Therapeutics$7.86$16.33107.76%Buy
GRPHLENZ Therapeutics$3.18$4.0025.79%Hold
CYTCyteir Therapeutics$3.02$2.00-33.77%Sell

CYT Forecast FAQ

Is Cyteir Therapeutics a good buy?

No, according to 1 Wall Street analysts, Cyteir Therapeutics (CYT) is considered a 'Sell'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of CYT's total ratings.

What is CYT's price target?

Cyteir Therapeutics (CYT) average price target is $2 with a range of $2 to $2, implying a -33.55% from its last price of $3.01. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Cyteir Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CYT stock, the company can go down by -33.55% (from the last price of $3.01 to the average price target of $2), down by -33.55% based on the highest stock price target, and down by -33.55% based on the lowest stock price target.

Can Cyteir Therapeutics stock reach $5?

CYT's average twelve months analyst stock price target of $2 does not support the claim that Cyteir Therapeutics can reach $5 in the near future.

What are Cyteir Therapeutics's analysts' financial forecasts?

CYT's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-16.214M (high $-16.214M, low $-16.214M), average SG&A $0 (high $0, low $0), and average EPS is $-0.45 (high $-0.45, low $-0.45).